{"transactions":[{"id":4622723,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Ordinary Shares","published_at":"2026-09-18T20:01:44.000Z","date":"2026-09-18","kind":"sale","planned":true,"acquired":false,"shares":3839,"price":16.71,"value":64149.69,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17 on September 16, 2026 and from $16.15 to $17.23 on September 18, 2026, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":134588,"source":{"system":"sec-edgar","filing":"0001628280-26-062700","document":"wk-form4_1789761701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1824673/000162828026062700/wk-form4_1789761701.xml","form_type":"4"}},{"id":4622722,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Ordinary Shares","published_at":"2026-09-18T20:01:44.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":731,"price":17.9,"value":13084.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17 on September 16, 2026 and from $16.15 to $17.23 on September 18, 2026, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":138427,"source":{"system":"sec-edgar","filing":"0001628280-26-062700","document":"wk-form4_1789761701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824673/000162828026062700/wk-form4_1789761701.xml","form_type":"4"}},{"id":728733,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Ordinary Shares","published_at":"2026-06-23T20:02:21.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":20549,"price":17.99,"value":369676.51,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.88 to $18.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":139158,"source":{"system":"sec-edgar","filing":"0001628280-26-044885","document":"wk-form4_1782244938.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026044885/wk-form4_1782244938.xml","form_type":"4"}},{"id":964659,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-17T21:43:02.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":78029,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This Option represents a right to purchase shares of the Issuer's Ordinary Shares and vests with respect to 1/48th of the Option on each monthly anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date."}],"balance_after":78029,"derivative":{"exercise_price":13.21,"expiration_date":"2035-12-15","underlying":"Ordinary Shares","underlying_shares":78029},"source":{"system":"sec-edgar","filing":"0001628280-25-057678","document":"wk-form4_1766007778.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025057678/wk-form4_1766007778.xml","form_type":"4"}},{"id":964658,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Ordinary Shares","published_at":"2025-12-17T21:43:02.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025,  subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date."}],"balance_after":159707,"source":{"system":"sec-edgar","filing":"0001628280-25-057678","document":"wk-form4_1766007778.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025057678/wk-form4_1766007778.xml","form_type":"4"}},{"id":964657,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Ordinary Shares","published_at":"2025-12-17T21:43:02.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":19507,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025,  subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date."}],"balance_after":153707,"source":{"system":"sec-edgar","filing":"0001628280-25-057678","document":"wk-form4_1766007778.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025057678/wk-form4_1766007778.xml","form_type":"4"}},{"id":974254,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T21:37:26.000Z","date":"2025-12-08","kind":"grant","planned":false,"acquired":true,"shares":172836,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase shares of the Issuer's ordinary shares and vests in 48 approximately equal monthly installments that commenced on December 8, 2025."}],"balance_after":172836,"derivative":{"exercise_price":13.17,"expiration_date":"2035-12-08","underlying":"Ordinary Shares","underlying_shares":172836},"source":{"system":"sec-edgar","filing":"0001628280-25-056333","document":"wk-form4_1765402643.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025056333/wk-form4_1765402643.xml","form_type":"4"}},{"id":1427806,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-08-20T20:27:39.000Z","date":"2024-08-19","kind":"sale","planned":true,"acquired":false,"shares":305,"price":46,"value":14030.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.53 to $46.45, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 116,875 unvested RSUs."}],"balance_after":132106,"source":{"system":"sec-edgar","filing":"0000950170-24-099127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024099127/ownership.xml","form_type":"4"}},{"id":1427805,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-08-20T20:27:39.000Z","date":"2024-08-19","kind":"sale","planned":true,"acquired":false,"shares":2400,"price":45.01,"value":108024.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $44.51 to $45.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4."}],"balance_after":132411,"source":{"system":"sec-edgar","filing":"0000950170-24-099127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024099127/ownership.xml","form_type":"4"}},{"id":1483642,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-06-11T23:34:02.000Z","date":"2024-06-11","kind":"sale","planned":false,"acquired":false,"shares":1823,"price":31.34,"value":57132.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $31.00 to $31.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 122,885 unvested RSUs."}],"balance_after":134811,"source":{"system":"sec-edgar","filing":"0000950170-24-072151","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024072151/ownership.xml","form_type":"4"}},{"id":1511660,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-05-18T01:03:32.000Z","date":"2024-05-16","kind":"sale","planned":true,"acquired":false,"shares":495,"price":28.59,"value":14152.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $28.51 to $28.70, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 126,967 unvested RSUs."}],"balance_after":136634,"source":{"system":"sec-edgar","filing":"0000950170-24-062075","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024062075/ownership.xml","form_type":"4"}},{"id":1511659,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-05-18T01:03:32.000Z","date":"2024-05-16","kind":"sale","planned":true,"acquired":false,"shares":2279,"price":28.2,"value":64267.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.50 to $28.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4."}],"balance_after":137129,"source":{"system":"sec-edgar","filing":"0000950170-24-062075","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024062075/ownership.xml","form_type":"4"}},{"id":1547894,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock option (right to buy)","published_at":"2024-04-05T01:06:10.000Z","date":"2023-07-11","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This transaction is being reported late due to an inadvertent administrative error."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option award was granted on July 11, 2023 and vests over four years in equal monthly installments, with the first vesting occurring on August 1, 2023 and the remaining vesting occurring each month subsequent to the first vesting date, subject to continuous service."}],"balance_after":35000,"derivative":{"exercise_price":11.79,"expiration_date":"2033-07-10","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0000950170-24-042032","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024042032/ownership.xml","form_type":"4"}},{"id":1578914,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock option (right to buy)","published_at":"2024-03-13T10:04:07.000Z","date":"2024-03-11","kind":"exercise","planned":true,"acquired":false,"shares":17825,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an IND application submitted to the FDA by the Company with respect to one ofitsproduct candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined thattheperformance condition had been achieved."}],"balance_after":0,"derivative":{"exercise_price":5.54,"expiration_date":"2030-07-30","underlying":"Common Stock","underlying_shares":17825},"source":{"system":"sec-edgar","filing":"0000950170-24-030484","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024030484/ownership.xml","form_type":"4"}},{"id":1578913,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock option (right to buy)","published_at":"2024-03-13T10:04:07.000Z","date":"2024-03-08","kind":"exercise","planned":true,"acquired":false,"shares":3841,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an IND application submitted to the FDA by the Company with respect to one ofitsproduct candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined thattheperformance condition had been achieved."}],"derivative":{"exercise_price":5.54,"expiration_date":"2030-07-30","underlying":"Common Stock","underlying_shares":3841},"source":{"system":"sec-edgar","filing":"0000950170-24-030484","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024030484/ownership.xml","form_type":"4"}},{"id":1578912,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock option (right to buy)","published_at":"2024-03-13T10:04:07.000Z","date":"2024-03-08","kind":"exercise","planned":true,"acquired":false,"shares":86159,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option was granted on July 31, 2020. The shares underlying the option vest over four years in equal quarterly installments beginning on October 31, 2020."}],"balance_after":12309,"derivative":{"exercise_price":5.54,"expiration_date":"2030-07-30","underlying":"Common Stock","underlying_shares":86159},"source":{"system":"sec-edgar","filing":"0000950170-24-030484","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024030484/ownership.xml","form_type":"4"}},{"id":1578911,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-03-13T10:04:07.000Z","date":"2024-03-11","kind":"sale","planned":true,"acquired":false,"shares":1776,"price":25.71,"value":45660.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.67 to $25.81, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Includes 132,976 unvested RSUs."}],"balance_after":139408,"source":{"system":"sec-edgar","filing":"0000950170-24-030484","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024030484/ownership.xml","form_type":"4"}},{"id":1578910,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-03-13T10:04:07.000Z","date":"2024-03-11","kind":"sale","planned":true,"acquired":false,"shares":17825,"price":25.48,"value":454181.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.14 to $26.09, inclusive."}],"balance_after":141184,"source":{"system":"sec-edgar","filing":"0000950170-24-030484","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024030484/ownership.xml","form_type":"4"}},{"id":1578909,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-03-13T10:04:07.000Z","date":"2024-03-11","kind":"exercise","planned":true,"acquired":true,"shares":17825,"price":5.54,"value":98750.5,"ownership":{"direct":true},"balance_after":159009,"source":{"system":"sec-edgar","filing":"0000950170-24-030484","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024030484/ownership.xml","form_type":"4"}},{"id":1578908,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-03-13T10:04:07.000Z","date":"2024-03-08","kind":"sale","planned":true,"acquired":false,"shares":689,"price":27.31,"value":18816.59,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.27 to $27.39, inclusive."}],"balance_after":141184,"source":{"system":"sec-edgar","filing":"0000950170-24-030484","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024030484/ownership.xml","form_type":"4"}},{"id":1578907,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-03-13T10:04:07.000Z","date":"2024-03-08","kind":"sale","planned":true,"acquired":false,"shares":54648,"price":26.72,"value":1460194.56,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.25 to $27.19, inclusive."}],"balance_after":141873,"source":{"system":"sec-edgar","filing":"0000950170-24-030484","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024030484/ownership.xml","form_type":"4"}},{"id":1578906,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-03-13T10:04:07.000Z","date":"2024-03-08","kind":"sale","planned":true,"acquired":false,"shares":34663,"price":25.46,"value":882519.98,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.25 to $26.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":196521,"source":{"system":"sec-edgar","filing":"0000950170-24-030484","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024030484/ownership.xml","form_type":"4"}},{"id":1578905,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-03-13T10:04:07.000Z","date":"2024-03-08","kind":"exercise","planned":true,"acquired":true,"shares":3841,"price":5.54,"value":21279.14,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.25 to $26.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":231184,"source":{"system":"sec-edgar","filing":"0000950170-24-030484","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024030484/ownership.xml","form_type":"4"}},{"id":1578904,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-03-13T10:04:07.000Z","date":"2024-03-08","kind":"exercise","planned":true,"acquired":true,"shares":86159,"price":5.54,"value":477320.86,"ownership":{"direct":true},"balance_after":227343,"source":{"system":"sec-edgar","filing":"0000950170-24-030484","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024030484/ownership.xml","form_type":"4"}},{"id":1584365,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-03-12T01:50:24.000Z","date":"2024-03-07","kind":"sale","planned":true,"acquired":false,"shares":2434,"price":25.85,"value":62918.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.84 to $26.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 137,058 unvested RSUs."}],"balance_after":141184,"source":{"system":"sec-edgar","filing":"0000950170-24-029607","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024029607/ownership.xml","form_type":"4"}},{"id":1607450,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock option (right to buy)","published_at":"2024-03-02T02:37:54.000Z","date":"2024-03-01","kind":"exercise","planned":true,"acquired":false,"shares":24260,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option was granted on February 26, 2019. The shares underlying the option vest over four years, with 25% of the shares vesting on February 1, 2020 and the remaining shares vesting in equal quarterly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":0.73,"expiration_date":"2029-02-25","underlying":"Common Stock","underlying_shares":24260},"source":{"system":"sec-edgar","filing":"0000950170-24-024299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024024299/ownership.xml","form_type":"4"}},{"id":1607449,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock option (right to buy)","published_at":"2024-03-02T02:37:54.000Z","date":"2024-02-29","kind":"exercise","planned":true,"acquired":false,"shares":4268,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option was granted on February 26, 2019. The shares underlying the option vest over four years, with 25% of the shares vesting on February 1, 2020 and the remaining shares vesting in equal quarterly installments thereafter."}],"balance_after":24260,"derivative":{"exercise_price":0.73,"expiration_date":"2029-02-25","underlying":"Common Stock","underlying_shares":4268},"source":{"system":"sec-edgar","filing":"0000950170-24-024299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024024299/ownership.xml","form_type":"4"}},{"id":1607448,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-03-02T02:37:54.000Z","date":"2024-03-01","kind":"sale","planned":true,"acquired":false,"shares":1442,"price":29.7,"value":42827.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $29.58 to $29.88, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 137,058 unvested RSUs."}],"balance_after":143618,"source":{"system":"sec-edgar","filing":"0000950170-24-024299","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024024299/ownership.xml","form_type":"4"}},{"id":1607447,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-03-02T02:37:54.000Z","date":"2024-03-01","kind":"sale","planned":true,"acquired":false,"shares":8715,"price":29.06,"value":253257.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $28.56 to $29.51, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 137,058 unvested RSUs."}],"balance_after":145060,"source":{"system":"sec-edgar","filing":"0000950170-24-024299","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024024299/ownership.xml","form_type":"4"}},{"id":1607446,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-03-02T02:37:54.000Z","date":"2024-03-01","kind":"sale","planned":true,"acquired":false,"shares":14103,"price":28.25,"value":398409.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.50 to $28.48, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 137,058 unvested RSUs."}],"balance_after":153775,"source":{"system":"sec-edgar","filing":"0000950170-24-024299","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024024299/ownership.xml","form_type":"4"}},{"id":1607445,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-03-02T02:37:54.000Z","date":"2024-03-01","kind":"exercise","planned":true,"acquired":true,"shares":24260,"price":0.73,"value":17709.8,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 137,058 unvested RSUs."}],"balance_after":167878,"source":{"system":"sec-edgar","filing":"0000950170-24-024299","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024024299/ownership.xml","form_type":"4"}},{"id":1607444,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-03-02T02:37:54.000Z","date":"2024-02-29","kind":"sale","planned":true,"acquired":false,"shares":4268,"price":27.5,"value":117370.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.50 to $27.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 137,058 unvested RSUs."}],"balance_after":143618,"source":{"system":"sec-edgar","filing":"0000950170-24-024299","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024024299/ownership.xml","form_type":"4"}},{"id":1607443,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-03-02T02:37:54.000Z","date":"2024-02-29","kind":"exercise","planned":true,"acquired":true,"shares":4268,"price":0.73,"value":3115.64,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 137,058 unvested RSUs."}],"balance_after":147886,"source":{"system":"sec-edgar","filing":"0000950170-24-024299","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024024299/ownership.xml","form_type":"4"}},{"id":1669741,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock option (right to buy)","published_at":"2024-01-27T00:48:29.000Z","date":"2024-01-26","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was granted on February 26, 2019. The shares underlying the option vest over four years, with 25% of the shares vesting on February 1, 2020 and the remaining shares vesting in equal quarterly installments thereafter."}],"balance_after":28528,"derivative":{"exercise_price":0.73,"expiration_date":"2029-02-25","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-24-008062","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024008062/ownership.xml","form_type":"4"}},{"id":1669740,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-01-27T00:48:29.000Z","date":"2024-01-26","kind":"sale","planned":true,"acquired":false,"shares":178,"price":25.14,"value":4474.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.01 to $25.25, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 143,067 unvested RSUs."}],"balance_after":143618,"source":{"system":"sec-edgar","filing":"0000950170-24-008062","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024008062/ownership.xml","form_type":"4"}},{"id":1669739,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-01-27T00:48:29.000Z","date":"2024-01-26","kind":"sale","planned":true,"acquired":false,"shares":19822,"price":24.52,"value":486035.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $24.00 to $24.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 143,067 unvested RSUs."}],"balance_after":143796,"source":{"system":"sec-edgar","filing":"0000950170-24-008062","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024008062/ownership.xml","form_type":"4"}},{"id":1669738,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-01-27T00:48:29.000Z","date":"2024-01-26","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":0.73,"value":14600.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 143,067 unvested RSUs."}],"balance_after":163618,"source":{"system":"sec-edgar","filing":"0000950170-24-008062","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024008062/ownership.xml","form_type":"4"}},{"id":1688104,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock option (right to buy)","published_at":"2024-01-05T02:47:38.000Z","date":"2024-01-04","kind":"exercise","planned":true,"acquired":false,"shares":2009,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option was granted on February 26, 2019. The shares underlying the option vest over four years, with 25% of the shares vesting on February 1, 2020 and the remaining shares vesting in equal quarterly installments thereafter."}],"balance_after":48528,"derivative":{"exercise_price":0.73,"expiration_date":"2029-02-25","underlying":"Common Stock","underlying_shares":2009},"source":{"system":"sec-edgar","filing":"0000950170-24-002278","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024002278/ownership.xml","form_type":"4"}},{"id":1688103,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock option (right to buy)","published_at":"2024-01-05T02:47:38.000Z","date":"2024-01-03","kind":"exercise","planned":true,"acquired":false,"shares":17991,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option was granted on February 26, 2019. The shares underlying the option vest over four years, with 25% of the shares vesting on February 1, 2020 and the remaining shares vesting in equal quarterly installments thereafter."}],"balance_after":50537,"derivative":{"exercise_price":0.73,"expiration_date":"2029-02-25","underlying":"Common Stock","underlying_shares":17991},"source":{"system":"sec-edgar","filing":"0000950170-24-002278","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024002278/ownership.xml","form_type":"4"}},{"id":1688102,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-01-05T02:47:38.000Z","date":"2024-01-04","kind":"sale","planned":true,"acquired":false,"shares":2009,"price":18.04,"value":36242.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.07, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 143,067 unvested RSUs."}],"balance_after":143618,"source":{"system":"sec-edgar","filing":"0000950170-24-002278","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024002278/ownership.xml","form_type":"4"}},{"id":1688101,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-01-05T02:47:38.000Z","date":"2024-01-04","kind":"exercise","planned":true,"acquired":true,"shares":2009,"price":0.73,"value":1466.57,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 143,067 unvested RSUs."}],"balance_after":145627,"source":{"system":"sec-edgar","filing":"0000950170-24-002278","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024002278/ownership.xml","form_type":"4"}},{"id":1688100,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-01-05T02:47:38.000Z","date":"2024-01-03","kind":"sale","planned":true,"acquired":false,"shares":10300,"price":19.03,"value":196009.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $19.00 to $19.25, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 143,067 unvested RSUs."}],"balance_after":143618,"source":{"system":"sec-edgar","filing":"0000950170-24-002278","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024002278/ownership.xml","form_type":"4"}},{"id":1688099,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-01-05T02:47:38.000Z","date":"2024-01-03","kind":"sale","planned":true,"acquired":false,"shares":7691,"price":18.34,"value":141052.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.50, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 143,067 unvested RSUs."}],"balance_after":153918,"source":{"system":"sec-edgar","filing":"0000950170-24-002278","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024002278/ownership.xml","form_type":"4"}},{"id":1688098,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-01-05T02:47:38.000Z","date":"2024-01-03","kind":"exercise","planned":true,"acquired":true,"shares":17991,"price":0.73,"value":13133.43,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 143,067 unvested RSUs."}],"balance_after":161609,"source":{"system":"sec-edgar","filing":"0000950170-24-002278","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024002278/ownership.xml","form_type":"4"}},{"id":1688097,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-01-05T02:47:38.000Z","date":"2024-01-02","kind":"sale","planned":true,"acquired":false,"shares":11900,"price":13.1,"value":155890.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $12.76 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 143,067 unvested RSUs."}],"balance_after":143618,"source":{"system":"sec-edgar","filing":"0000950170-24-002278","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024002278/ownership.xml","form_type":"4"}},{"id":1714460,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-12-12T22:34:48.000Z","date":"2023-12-11","kind":"sale","planned":false,"acquired":false,"shares":1245,"price":10.72,"value":13346.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $10.72 to $10.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 143,067 unvested RSUs."}],"balance_after":155518,"source":{"system":"sec-edgar","filing":"0001209191-23-058330","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123058330/doc4.xml","form_type":"4"}},{"id":1739239,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-16T21:34:50.000Z","date":"2023-11-15","kind":"grant","planned":false,"acquired":true,"shares":37445,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on November 15, 2023. The shares underlying the option are scheduled to vest over four years in equal monthly installments through November 15, 2027."}],"balance_after":37445,"derivative":{"exercise_price":10.88,"expiration_date":"2033-11-14","underlying":"Common Stock","underlying_shares":37445},"source":{"system":"sec-edgar","filing":"0001209191-23-055530","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123055530/doc4.xml","form_type":"4"}},{"id":1739238,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-11-16T21:34:50.000Z","date":"2023-11-15","kind":"grant","planned":false,"acquired":true,"shares":96158,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Common Stock issuable under 96,158 restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on February 15, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 147,149 unvested RSUs."}],"balance_after":156763,"source":{"system":"sec-edgar","filing":"0001209191-23-055530","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123055530/doc4.xml","form_type":"4"}},{"id":1776298,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-09-20T20:49:15.000Z","date":"2023-09-18","kind":"sale","planned":false,"acquired":false,"shares":1261,"price":9.41,"value":11866.01,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 50,991 unvested RSUs."}],"balance_after":60605,"source":{"system":"sec-edgar","filing":"0001209191-23-050173","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123050173/doc4.xml","form_type":"4"}},{"id":1782169,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-09-13T23:53:04.000Z","date":"2023-09-12","kind":"sale","planned":true,"acquired":false,"shares":1266,"price":10.41,"value":13179.06,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $10.08 to $10.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 55,244 unvested RSUs."}],"balance_after":61866,"source":{"system":"sec-edgar","filing":"0001209191-23-049360","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123049360/doc4.xml","form_type":"4"}},{"id":1856023,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-06-14T22:40:50.000Z","date":"2023-06-13","kind":"sale","planned":true,"acquired":false,"shares":1259,"price":12.43,"value":15649.37,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 59,326 unvested RSUs."}],"balance_after":63132,"source":{"system":"sec-edgar","filing":"0001209191-23-037167","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123037167/doc4.xml","form_type":"4"}},{"id":1856022,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-06-14T22:40:50.000Z","date":"2023-06-12","kind":"sale","planned":true,"acquired":false,"shares":1000,"price":13,"value":13000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $12.95 to $13.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 59,326 unvested RSUs."}],"balance_after":64391,"source":{"system":"sec-edgar","filing":"0001209191-23-037167","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123037167/doc4.xml","form_type":"4"}},{"id":1952355,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-03-15T21:50:33.000Z","date":"2023-03-14","kind":"sale","acquired":false,"shares":1209,"price":13.33,"value":16115.97,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 63,408 unvested RSUs."}],"balance_after":65391,"source":{"system":"sec-edgar","filing":"0001209191-23-018981","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123018981/doc4.xml","form_type":"4"}},{"id":1952354,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-03-15T21:50:33.000Z","date":"2023-03-13","kind":"sale","acquired":false,"shares":1000,"price":13,"value":13000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.00 to $13.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 63,408 unvested RSUs."}],"balance_after":66600,"source":{"system":"sec-edgar","filing":"0001209191-23-018981","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123018981/doc4.xml","form_type":"4"}},{"id":2048792,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-23T13:27:05.000Z","date":"2023-01-18","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This is an inadvertent late filing due to an administrative error."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted on February 26, 2019. The shares underlying the option vest over four years, with 25% of the shares vesting on February 1, 2020 and the remaining shares vesting in equal quarterly installments thereafter."}],"balance_after":68528,"derivative":{"exercise_price":0.73,"expiration_date":"2029-02-25","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-23-004345","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123004345/doc4.xml","form_type":"4"}},{"id":2048791,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-01-23T13:27:05.000Z","date":"2023-01-18","kind":"sale","acquired":false,"shares":10000,"price":14.03,"value":140300.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This is an inadvertent late filing due to an administrative error."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $14.00 to $14.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4."}],"balance_after":67600,"source":{"system":"sec-edgar","filing":"0001209191-23-004345","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123004345/doc4.xml","form_type":"4"}},{"id":2048790,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-01-23T13:27:05.000Z","date":"2023-01-18","kind":"exercise","acquired":true,"shares":10000,"price":0.73,"value":7300.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This is an inadvertent late filing due to an administrative error."}],"balance_after":77600,"source":{"system":"sec-edgar","filing":"0001209191-23-004345","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123004345/doc4.xml","form_type":"4"}},{"id":2056568,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-01-11T21:56:59.000Z","date":"2023-01-09","kind":"sale","acquired":false,"shares":30150,"price":11.57,"value":348835.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $11.12 to $11.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 67,490 unvested RSUs."}],"balance_after":67600,"source":{"system":"sec-edgar","filing":"0001209191-23-003013","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123003013/doc4.xml","form_type":"4"}},{"id":2088163,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2022-12-13T22:05:28.000Z","date":"2022-12-09","kind":"grant","acquired":true,"shares":63000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on December 9, 2022. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2026."}],"balance_after":63000,"derivative":{"exercise_price":10.72,"expiration_date":"2032-12-08","underlying":"Common Stock","underlying_shares":63000},"source":{"system":"sec-edgar","filing":"0001209191-22-060972","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919122060972/doc4.xml","form_type":"4"}},{"id":2088162,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-12-13T22:05:28.000Z","date":"2022-12-12","kind":"sale","acquired":false,"shares":472,"price":10.87,"value":5130.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 67,490 unvested RSUs."}],"balance_after":97750,"source":{"system":"sec-edgar","filing":"0001209191-22-060972","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919122060972/doc4.xml","form_type":"4"}},{"id":2088161,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-12-13T22:05:28.000Z","date":"2022-12-09","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Common Stock issuable under 40,000 restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 69,072 unvested RSUs."}],"balance_after":98222,"source":{"system":"sec-edgar","filing":"0001209191-22-060972","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919122060972/doc4.xml","form_type":"4"}},{"id":2153526,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-09-21T20:08:54.000Z","date":"2022-09-20","kind":"disposition_to_issuer","acquired":false,"shares":1246,"price":13.7,"value":17070.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 20, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $13.70 to $13.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 29,072 unvested RSUs."}],"balance_after":58222,"source":{"system":"sec-edgar","filing":"0001209191-22-050891","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919122050891/doc4.xml","form_type":"4"}},{"id":2158509,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-09-15T21:27:33.000Z","date":"2022-09-15","kind":"disposition_to_issuer","acquired":false,"shares":494,"price":14.05,"value":6940.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 15, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $14.05 to $14.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 33,325 unvested RSUs."}],"balance_after":59468,"source":{"system":"sec-edgar","filing":"0001209191-22-050122","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919122050122/doc4.xml","form_type":"4"}},{"id":2212181,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-06T22:21:58.000Z","date":"2022-07-05","kind":"grant","acquired":true,"shares":21666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved."}],"balance_after":21666,"derivative":{"exercise_price":5.54,"expiration_date":"2030-07-30","underlying":"Common Stock","underlying_shares":21666},"source":{"system":"sec-edgar","filing":"0001209191-22-041339","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919122041339/doc4.xml","form_type":"4"}},{"id":2231585,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-06-16T00:04:34.000Z","date":"2022-06-14","kind":"disposition_to_issuer","acquired":false,"shares":504,"price":4.95,"value":2494.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 34,907 unvested RSUs."}],"balance_after":59962,"source":{"system":"sec-edgar","filing":"0001209191-22-037150","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919122037150/doc4.xml","form_type":"4"}},{"id":2335685,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-03-14T21:09:11.000Z","date":"2022-03-11","kind":"sale","acquired":false,"shares":481,"price":8.73,"value":4199.13,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on March 11, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $8.65 to $8.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 36,489 unvested RSUs."}],"balance_after":60466,"source":{"system":"sec-edgar","filing":"0001209191-22-018536","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919122018536/doc4.xml","form_type":"4"}},{"id":2473655,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2021-12-14T21:22:18.000Z","date":"2021-12-10","kind":"grant","acquired":true,"shares":37967,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on December 10, 2021. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2025."}],"balance_after":37967,"derivative":{"exercise_price":13.12,"expiration_date":"2031-12-09","underlying":"Common Stock","underlying_shares":37967},"source":{"system":"sec-edgar","filing":"0001209191-21-069425","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919121069425/doc4.xml","form_type":"4"}},{"id":2473654,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-12-14T21:22:18.000Z","date":"2021-12-10","kind":"grant","acquired":true,"shares":25311,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Common Stock issuable under 25,311 restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 38,070 unvested RSUs. Each unvested RSU represents the right to receive one share of Common Stock upon vesting."}],"balance_after":60947,"source":{"system":"sec-edgar","filing":"0001209191-21-069425","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919121069425/doc4.xml","form_type":"4"}},{"id":2562152,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-09-23T00:02:57.000Z","date":"2021-09-21","kind":"sale","acquired":false,"shares":729,"price":16.11,"value":11744.19,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 21, 2021 on behalf of a group of employees of the issuer to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $15.87 to $16.36, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 12,759 unvested RSUs."}],"balance_after":35636,"source":{"system":"sec-edgar","filing":"0001209191-21-057325","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919121057325/doc4.xml","form_type":"4"}},{"id":2562151,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-09-23T00:02:57.000Z","date":"2021-09-20","kind":"sale","acquired":false,"shares":545,"price":15.61,"value":8507.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 20, 2021 on behalf of a group of employees of the issuer to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $15.22 to $16.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in footnote (2) and (4) of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 12,759 unvested RSUs."}],"balance_after":36365,"source":{"system":"sec-edgar","filing":"0001209191-21-057325","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919121057325/doc4.xml","form_type":"4"}},{"id":2635012,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2021-07-13T20:22:39.000Z","date":"2021-07-10","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on July 10, 2021. The shares underlying the option are scheduled to vest over four years in equal quarterly installments from July 1, 2021."}],"balance_after":25000,"derivative":{"exercise_price":21.01,"expiration_date":"2031-07-09","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-21-046494","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919121046494/doc4.xml","form_type":"4"}},{"id":3027146,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2020-09-18T21:11:47.000Z","date":"2020-09-16","kind":"grant","acquired":true,"shares":52787,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on September 16, 2020. The shares underlying the option are scheduled to vest over four years in equal monthly installments through September 16, 2024."}],"balance_after":52787,"derivative":{"exercise_price":19,"expiration_date":"2030-09-15","underlying":"Common Stock","underlying_shares":52787},"source":{"system":"sec-edgar","filing":"0000899243-20-025737","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000089924320025737/doc4.xml","form_type":"4"}},{"id":3027145,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35927,"kind":"person","name":"McNeill Jonathan","position":1,"cik":"0001824673","reported_name":"McNeill Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-09-18T21:11:47.000Z","date":"2020-09-17","kind":"grant","acquired":true,"shares":17012,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Common Stock issuable under 17,012 restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on September 17, 2021."}],"balance_after":36910,"source":{"system":"sec-edgar","filing":"0000899243-20-025737","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000089924320025737/doc4.xml","form_type":"4"}}]}